 | • レポートコード：GIR-105X13116 • 出版社/出版日： / 2021年5月 • レポート形態：英文、PDF、104ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：Pharma & Healthcare |
| Single User | ￥515,040 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥772,560 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,030,080 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料では、卵巣がん治療薬のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。卵巣がん治療薬の種類別市場規模（アルキル化剤、有糸分裂阻害剤、抗リウマチ剤、抗乾癬剤、VEGF / VEGFR阻害剤、PARP阻害剤、抗腫瘍剤、その他）、用途別市場規模（病院薬局、ドラッグストア、オンライン薬局、その他）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・卵巣がん治療薬の市場概要 ・企業情報（企業概要、製品概要、販売量、価格、売上）：Allergan plc、Pfizer, Inc.、Merck KGaA、AstraZeneca、F. Hoffmann-La Roche AG、Johnson & Johnson、Syndax Pharmaceuticals, Inc.、Clovis Oncology ・企業別市場シェア ・地域別市場分析2016年-2026年 ・種類別分析2016年-2026年：アルキル化剤、有糸分裂阻害剤、抗リウマチ剤、抗乾癬剤、VEGF / VEGFR阻害剤、PARP阻害剤、抗腫瘍剤、その他 ・用途別分析2016年-2026年：病院薬局、ドラッグストア、オンライン薬局、その他 ・卵巣がん治療薬の北米市場規模2016年-2026年：アメリカ、カナダ、メキシコ ・卵巣がん治療薬のヨーロッパ市場規模2016年-2026年：ドイツ、イギリス、フランス、ロシア、イタリア ・卵巣がん治療薬のアジア市場規模2016年-2026年：中国、日本、韓国、インド、東南アジア、オーストラリア ・卵巣がん治療薬の南米市場規模2016年-2026年：ブラジル、アルゼンチン ・卵巣がん治療薬の中東・アフリカ市場規模2016年-2026年：サウジアラビア、トルコ、エジプト、南アフリカ ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論 |
The Ovarian Cancer Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our latest research, the global Ovarian Cancer Drugs size is estimated to be xx million in 2020 from USD xx million in 2019, with a change of XX% between 2019 and 2020. The global Ovarian Cancer Drugs market size is expected to grow at a CAGR of xx% for the next five years.
Market segmentation
Ovarian Cancer Drugs market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Alkylating Agents
Mitotic Inhibitors
Antirheumatics
Antipsoriatics
VEGF/VEGFR Inhibitors
PARP Inhibitors
Antineoplastics
Others
Market segment by Application can be divided into
Hospital Pharmacies
Drug Stores
Online Pharmacies
Others
The key market players for global Ovarian Cancer Drugs market are listed below:
Allergan plc
Pfizer, Inc.
Merck KGaA
AstraZeneca
F. Hoffmann-La Roche AG
Johnson & Johnson
Syndax Pharmaceuticals, Inc.
Clovis Oncology
Market segment by Region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
1 Market Overview
1.1 Ovarian Cancer Drugs Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Ovarian Cancer Drugs Revenue by Type: 2019 Versus 2021 Versus 2026
1.2.2 Alkylating Agents
1.2.3 Mitotic Inhibitors
1.2.4 Antirheumatics
1.2.5 Antipsoriatics
1.2.6 VEGF/VEGFR Inhibitors
1.2.7 PARP Inhibitors
1.2.8 Antineoplastics
1.2.9 Others
1.3 Market Analysis by Application
1.3.1 Overview: Global Ovarian Cancer Drugs Revenue by Application: 2019 Versus 2021 Versus 2026
1.3.2 Hospital Pharmacies
1.3.3 Drug Stores
1.3.4 Online Pharmacies
1.3.5 Others
1.4 Global Ovarian Cancer Drugs Market Size & Forecast
1.4.1 Global Ovarian Cancer Drugs Sales in Value (2016-2026))
1.4.2 Global Ovarian Cancer Drugs Sales in Volume (2016-2026)
1.4.3 Global Ovarian Cancer Drugs Price by Type (2016-2026) & (USD/Unit)
1.5 Global Ovarian Cancer Drugs Production Capacity Analysis
1.5.1 Global Ovarian Cancer Drugs Total Production Capacity (2016-2026)
1.5.2 Global Ovarian Cancer Drugs Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 Ovarian Cancer Drugs Market Drivers
1.6.2 Ovarian Cancer Drugs Market Restraints
1.6.3 Ovarian Cancer Drugs Trends Analysis
2 Manufacturers Profiles
2.1 Allergan plc
2.1.1 Allergan plc Details
2.1.2 Allergan plc Major Business
2.1.3 Allergan plc Ovarian Cancer Drugs Product and Services
2.1.4 Allergan plc Ovarian Cancer Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
2.2 Pfizer, Inc.
2.2.1 Pfizer, Inc. Details
2.2.2 Pfizer, Inc. Major Business
2.2.3 Pfizer, Inc. Ovarian Cancer Drugs Product and Services
2.2.4 Pfizer, Inc. Ovarian Cancer Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
2.3 Merck KGaA
2.3.1 Merck KGaA Details
2.3.2 Merck KGaA Major Business
2.3.3 Merck KGaA Ovarian Cancer Drugs Product and Services
2.3.4 Merck KGaA Ovarian Cancer Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
2.4 AstraZeneca
2.4.1 AstraZeneca Details
2.4.2 AstraZeneca Major Business
2.4.3 AstraZeneca Ovarian Cancer Drugs Product and Services
2.4.4 AstraZeneca Ovarian Cancer Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
2.5 F. Hoffmann-La Roche AG
2.5.1 F. Hoffmann-La Roche AG Details
2.5.2 F. Hoffmann-La Roche AG Major Business
2.5.3 F. Hoffmann-La Roche AG Ovarian Cancer Drugs Product and Services
2.5.4 F. Hoffmann-La Roche AG Ovarian Cancer Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
2.6 Johnson & Johnson
2.6.1 Johnson & Johnson Details
2.6.2 Johnson & Johnson Major Business
2.6.3 Johnson & Johnson Ovarian Cancer Drugs Product and Services
2.6.4 Johnson & Johnson Ovarian Cancer Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
2.7 Syndax Pharmaceuticals, Inc.
2.7.1 Syndax Pharmaceuticals, Inc. Details
2.7.2 Syndax Pharmaceuticals, Inc. Major Business
2.7.3 Syndax Pharmaceuticals, Inc. Ovarian Cancer Drugs Product and Services
2.7.4 Syndax Pharmaceuticals, Inc. Ovarian Cancer Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
2.8 Clovis Oncology
2.8.1 Clovis Oncology Details
2.8.2 Clovis Oncology Major Business
2.8.3 Clovis Oncology Ovarian Cancer Drugs Product and Services
2.8.4 Clovis Oncology Ovarian Cancer Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
3 Ovarian Cancer Drugs Sales by Manufacturer
3.1 Global Ovarian Cancer Drugs Sales in Volume by Manufacturer (2019-2021e)
3.2 Global Ovarian Cancer Drugs Revenue by Manufacturer (2019-2021e)
3.3 Key Manufacturer Market Position in Ovarian Cancer Drugs
3.4 Market Concentration Rate
3.4.1 Top 3 Ovarian Cancer Drugs Manufacturer Market Share
3.4.2 Top 6 Ovarian Cancer Drugs Manufacturer Market Share
3.5 Global Ovarian Cancer Drugs Production Capacity by Company
3.6 Manufacturer by Geography: Head Office and Ovarian Cancer Drugs Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global Ovarian Cancer Drugs Market Size by Region
4.1.1 Global Ovarian Cancer Drugs Sales in Volume by Region (2016-2026)
4.1.2 Global Ovarian Cancer Drugs Revenue by Region (2016-2026)
4.2 North America Ovarian Cancer Drugs Revenue (2016-2026)
4.3 Europe Ovarian Cancer Drugs Revenue (2016-2026)
4.4 Asia-Pacific Ovarian Cancer Drugs Revenue (2016-2026)
4.5 South America Ovarian Cancer Drugs Revenue (2016-2026)
4.6 Middle East and Africa Ovarian Cancer Drugs Revenue (2016-2026)
5 Market Segment by Type
5.1 Global Ovarian Cancer Drugs Sales in Volume by Type (2016-2026)
5.2 Global Ovarian Cancer Drugs Revenue by Type (2016-2026)
5.3 Global Ovarian Cancer Drugs Price by Type (2016-2026)
6 Market Segment by Application
6.1 Global Ovarian Cancer Drugs Sales in Volume by Application (2016-2026)
6.2 Global Ovarian Cancer Drugs Revenue by Application (2016-2026)
6.3 Global Ovarian Cancer Drugs Price by Application (2016-2026)
7 North America by Country, by Type, and by Application
7.1 North America Ovarian Cancer Drugs Sales by Type (2016-2026)
7.2 North America Ovarian Cancer Drugs Sales by Application (2016-2026)
7.3 North America Ovarian Cancer Drugs Market Size by Country
7.3.1 North America Ovarian Cancer Drugs Sales in Volume by Country (2016-2026)
7.3.2 North America Ovarian Cancer Drugs Revenue by Country (2016-2026)
7.3.3 United States Market Size and Forecast (2016-2026)
7.3.4 Canada Market Size and Forecast (2016-2026)
7.3.5 Mexico Market Size and Forecast (2016-2026)
8 Europe by Country, by Type, and by Application
8.1 Europe Ovarian Cancer Drugs Sales by Type (2016-2026)
8.2 Europe Ovarian Cancer Drugs Sales by Application (2016-2026)
8.3 Europe Ovarian Cancer Drugs Market Size by Country
8.3.1 Europe Ovarian Cancer Drugs Sales in Volume by Country (2016-2026)
8.3.2 Europe Ovarian Cancer Drugs Revenue by Country (2016-2026)
8.3.3 Germany Market Size and Forecast (2016-2026)
8.3.4 France Market Size and Forecast (2016-2026)
8.3.5 United Kingdom Market Size and Forecast (2016-2026)
8.3.6 Russia Market Size and Forecast (2016-2026)
8.3.7 Italy Market Size and Forecast (2016-2026)
9 Asia-Pacific by Country, by Type, and by Application
9.1 Asia-Pacific Ovarian Cancer Drugs Sales by Type (2016-2026)
9.2 Asia-Pacific Ovarian Cancer Drugs Sales by Application (2016-2026)
9.3 Asia-Pacific Ovarian Cancer Drugs Market Size by Region
9.3.1 Asia-Pacific Ovarian Cancer Drugs Sales in Volume by Region (2016-2026)
9.3.2 Asia-Pacific Ovarian Cancer Drugs Revenue by Region (2016-2026)
9.3.3 China Market Size and Forecast (2016-2026)
9.3.4 Japan Market Size and Forecast (2016-2026)
9.3.5 Korea Market Size and Forecast (2016-2026)
9.3.6 India Market Size and Forecast (2016-2026)
9.3.7 Southeast Asia Market Size and Forecast (2016-2026)
9.3.8 Australia Market Size and Forecast (2016-2026)
10 South America by Country, by Type, and by Application
10.1 South America Ovarian Cancer Drugs Sales by Type (2016-2026)
10.2 South America Ovarian Cancer Drugs Sales by Application (2016-2026)
10.3 South America Ovarian Cancer Drugs Market Size by Country
10.3.1 South America Ovarian Cancer Drugs Sales in Volume by Country (2016-2026)
10.3.2 South America Ovarian Cancer Drugs Revenue by Country (2016-2026)
10.3.3 Brazil Market Size and Forecast (2016-2026)
10.3.4 Argentina Market Size and Forecast (2016-2026)
11 Middle East & Africa by Country, by Type, and by Application
11.1 Middle East & Africa Ovarian Cancer Drugs Sales by Type (2016-2026)
11.2 Middle East & Africa Ovarian Cancer Drugs Sales by Application (2016-2026)
11.3 Middle East & Africa Ovarian Cancer Drugs Market Size by Country
11.3.1 Middle East & Africa Ovarian Cancer Drugs Sales in Volume by Country (2016-2026)
11.3.2 Middle East & Africa Ovarian Cancer Drugs Revenue by Country (2016-2026)
11.3.3 Turkey Market Size and Forecast (2016-2026)
11.3.4 Egypt Market Size and Forecast (2016-2026)
11.3.5 Saudi Arabia Market Size and Forecast (2016-2026)
11.3.6 South Africa Market Size and Forecast (2016-2026)
12 Sales Channel, Distributors, Traders and Dealers
12.1 Sales Channel
12.1.1 Direct Marketing
12.1.2 Indirect Marketing
12.2 Ovarian Cancer Drugs Typical Distributors
12.3 Ovarian Cancer Drugs Typical Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
Table 1. Global Ovarian Cancer Drugs Revenue by Type, (USD Million), 2021-2026
Table 2. Global Ovarian Cancer Drugs Revenue by Application, (USD Million), 2021-2026
Table 3. Allergan plc Basic Information, Manufacturing Base and Competitors
Table 4. Allergan plc Major Business
Table 5. Allergan plc Ovarian Cancer Drugs Product and Services
Table 6. Allergan plc Ovarian Cancer Drugs Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 7. Pfizer, Inc. Basic Information, Manufacturing Base and Competitors
Table 8. Pfizer, Inc. Major Business
Table 9. Pfizer, Inc. Ovarian Cancer Drugs Product and Services
Table 10. Pfizer, Inc. Ovarian Cancer Drugs Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 11. Merck KGaA Basic Information, Manufacturing Base and Competitors
Table 12. Merck KGaA Major Business
Table 13. Merck KGaA Ovarian Cancer Drugs Product and Services
Table 14. Merck KGaA Ovarian Cancer Drugs Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 15. AstraZeneca Basic Information, Manufacturing Base and Competitors
Table 16. AstraZeneca Major Business
Table 17. AstraZeneca Ovarian Cancer Drugs Product and Services
Table 18. AstraZeneca Ovarian Cancer Drugs Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 19. F. Hoffmann-La Roche AG Basic Information, Manufacturing Base and Competitors
Table 20. F. Hoffmann-La Roche AG Major Business
Table 21. F. Hoffmann-La Roche AG Ovarian Cancer Drugs Product and Services
Table 22. F. Hoffmann-La Roche AG Ovarian Cancer Drugs Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 23. Johnson & Johnson Basic Information, Manufacturing Base and Competitors
Table 24. Johnson & Johnson Major Business
Table 25. Johnson & Johnson Ovarian Cancer Drugs Product and Services
Table 26. Johnson & Johnson Ovarian Cancer Drugs Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 27. Syndax Pharmaceuticals, Inc. Basic Information, Manufacturing Base and Competitors
Table 28. Syndax Pharmaceuticals, Inc. Major Business
Table 29. Syndax Pharmaceuticals, Inc. Ovarian Cancer Drugs Product and Services
Table 30. Syndax Pharmaceuticals, Inc. Ovarian Cancer Drugs Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 31. Clovis Oncology Basic Information, Manufacturing Base and Competitors
Table 32. Clovis Oncology Major Business
Table 33. Clovis Oncology Ovarian Cancer Drugs Product and Services
Table 34. Clovis Oncology Ovarian Cancer Drugs Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 35. Global Ovarian Cancer Drugs Sales by Manufacturer (2019-2021e) & (K Units)
Table 36. Global Ovarian Cancer Drugs Revenue by Manufacturer (2019-2021e) & (USD Million)
Table 37. Market Position of Manufacturers in Ovarian Cancer Drugs, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2020
Table 38. Global Ovarian Cancer Drugs Production Capacity by Company, (K Units): 2020 VS 2021
Table 39. Head Office and Ovarian Cancer Drugs Production Site of Key Manufacturer
Table 40. Global Ovarian Cancer Drugs Sales by Region (2016-2021e) & (K Units)
Table 41. Global Ovarian Cancer Drugs Sales by Region (2021-2026) & (K Units)
Table 42. Global Ovarian Cancer Drugs Revenue by Region (2016-2021e) & (USD Million)
Table 43. Global Ovarian Cancer Drugs Revenue by Region (2021-2026) & (USD Million)
Table 44. Global Ovarian Cancer Drugs Sales by Type (2016-2021e) & (K Units)
Table 45. Global Ovarian Cancer Drugs Sales by Type (2021-2026) & (K Units)
Table 46. Global Ovarian Cancer Drugs Revenue by Type (2016-2021e) & (USD Million)
Table 47. Global Ovarian Cancer Drugs Revenue by Type (2021-2026) & (USD Million)
Table 48. Global Ovarian Cancer Drugs Price by Type (2016-2021e) & (USD/Unit)
Table 49. Global Ovarian Cancer Drugs Price by Type (2021-2026) & (USD/Unit)
Table 50. Global Ovarian Cancer Drugs Sales by Application (2016-2021e) & (K Units)
Table 51. Global Ovarian Cancer Drugs Sales by Application (2021-2026) & (K Units)
Table 52. Global Ovarian Cancer Drugs Revenue by Application (2016-2021e) & (USD Million)
Table 53. Global Ovarian Cancer Drugs Revenue by Application (2021-2026) & (USD Million)
Table 54. Global Ovarian Cancer Drugs Price by Application (2016-2021e) & (USD/Unit)
Table 55. Global Ovarian Cancer Drugs Price by Application (2021-2026) & (USD/Unit)
Table 56. North America Ovarian Cancer Drugs Sales by Country (2016-2021e) & (K Units)
Table 57. North America Ovarian Cancer Drugs Sales by Country (2021-2026) & (K Units)
Table 58. North America Ovarian Cancer Drugs Revenue by Country (2016-2021e) & (USD Million)
Table 59. North America Ovarian Cancer Drugs Revenue by Country (2021-2026) & (USD Million)
Table 60. North America Ovarian Cancer Drugs Sales by Type (2016-2021e) & (K Units)
Table 61. North America Ovarian Cancer Drugs Sales by Type (2021-2026) & (K Units)
Table 62. North America Ovarian Cancer Drugs Sales by Application (2016-2021e) & (K Units)
Table 63. North America Ovarian Cancer Drugs Sales by Application (2021-2026) & (K Units)
Table 64. Europe Ovarian Cancer Drugs Sales by Country (2016-2021e) & (K Units)
Table 65. Europe Ovarian Cancer Drugs Sales by Country (2021-2026) & (K Units)
Table 66. Europe Ovarian Cancer Drugs Revenue by Country (2016-2021e) & (USD Million)
Table 67. Europe Ovarian Cancer Drugs Revenue by Country (2021-2026) & (USD Million)
Table 68. Europe Ovarian Cancer Drugs Sales by Type (2016-2021e) & (K Units)
Table 69. Europe Ovarian Cancer Drugs Sales by Type (2021-2026) & (K Units)
Table 70. Europe Ovarian Cancer Drugs Sales by Application (2016-2021e) & (K Units)
Table 71. Europe Ovarian Cancer Drugs Sales by Application (2021-2026) & (K Units)
Table 72. Asia-Pacific Ovarian Cancer Drugs Sales by Region (2016-2021e) & (K Units)
Table 73. Asia-Pacific Ovarian Cancer Drugs Sales by Region (2021-2026) & (K Units)
Table 74. Asia-Pacific Ovarian Cancer Drugs Revenue by Region (2016-2021e) & (USD Million)
Table 75. Asia-Pacific Ovarian Cancer Drugs Revenue by Region (2021-2026) & (USD Million)
Table 76. Asia-Pacific Ovarian Cancer Drugs Sales by Type (2016-2021e) & (K Units)
Table 77. Asia-Pacific Ovarian Cancer Drugs Sales by Type (2021-2026) & (K Units)
Table 78. Asia-Pacific Ovarian Cancer Drugs Sales by Application (2016-2021e) & (K Units)
Table 79. Asia-Pacific Ovarian Cancer Drugs Sales by Application (2021-2026) & (K Units)
Table 80. South America Ovarian Cancer Drugs Sales by Country (2016-2021e) & (K Units)
Table 81. South America Ovarian Cancer Drugs Sales by Country (2021-2026) & (K Units)
Table 82. South America Ovarian Cancer Drugs Revenue by Country (2016-2021e) & (USD Million)
Table 83. South America Ovarian Cancer Drugs Revenue by Country (2021-2026) & (USD Million)
Table 84. South America Ovarian Cancer Drugs Sales by Type (2016-2021e) & (K Units)
Table 85. South America Ovarian Cancer Drugs Sales by Type (2021-2026) & (K Units)
Table 86. South America Ovarian Cancer Drugs Sales by Application (2016-2021e) & (K Units)
Table 87. South America Ovarian Cancer Drugs Sales by Application (2021-2026) & (K Units)
Table 88. Middle East & Africa Ovarian Cancer Drugs Sales by Country (2016-2021e) & (K Units)
Table 89. Middle East & Africa Ovarian Cancer Drugs Sales by Country (2021-2026) & (K Units)
Table 90. Middle East & Africa Ovarian Cancer Drugs Revenue by Country (2016-2021e) & (USD Million)
Table 91. Middle East & Africa Ovarian Cancer Drugs Revenue by Country (2021-2026) & (USD Million)
Table 92. Middle East & Africa Ovarian Cancer Drugs Sales by Type (2016-2021e) & (K Units)
Table 93. Middle East & Africa Ovarian Cancer Drugs Sales by Type (2021-2026) & (K Units)
Table 94. Middle East & Africa Ovarian Cancer Drugs Sales by Application (2016-2021e) & (K Units)
Table 95. Middle East & Africa Ovarian Cancer Drugs Sales by Application (2021-2026) & (K Units)
Table 96. Direct Channel Pros & Cons
Table 97. Indirect Channel Pros & Cons
Table 98. Ovarian Cancer Drugs Typical Distributors
Table 99. Ovarian Cancer Drugs Typical Customers
List of Figures
Figure 1. Ovarian Cancer Drugs Picture
Figure 2. Global Ovarian Cancer Drugs Sales Market Share by Type in 2020
Figure 3. Alkylating Agents
Figure 4. Mitotic Inhibitors
Figure 5. Antirheumatics
Figure 6. Antipsoriatics
Figure 7. VEGF/VEGFR Inhibitors
Figure 8. PARP Inhibitors
Figure 9. Antineoplastics
Figure 10. Others
Figure 11. Global Ovarian Cancer Drugs Sales Market Share by Application in 2020
Figure 12. Hospital Pharmacies
Figure 13. Drug Stores
Figure 14. Online Pharmacies
Figure 15. Others
Figure 16. Global Ovarian Cancer Drugs Market Size, (USD Million) & (K Units): 2020 VS 2021 VS 2026
Figure 17. Global Ovarian Cancer Drugs Market Size and Forecast (2016-2026) & (USD Million)
Figure 18. United States Ovarian Cancer Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 19. Canada Ovarian Cancer Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 20. Mexico Ovarian Cancer Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 21. Germany Ovarian Cancer Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 22. France Ovarian Cancer Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 23. United Kingdom Ovarian Cancer Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 24. Russia Ovarian Cancer Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 25. Italy Ovarian Cancer Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 26. China Ovarian Cancer Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 27. Japan Ovarian Cancer Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 28. Korea Ovarian Cancer Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 29. India Ovarian Cancer Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 30. Southeast Asia Ovarian Cancer Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 31. Australia Ovarian Cancer Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 32. Brazil Ovarian Cancer Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 33. Egypt Ovarian Cancer Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 34. Saudi Arabia Ovarian Cancer Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 35. South Africa Ovarian Cancer Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 36. Turkey Ovarian Cancer Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 37. Global Ovarian Cancer Drugs Sales (2016-2026) & (K Units)
Figure 38. Global Ovarian Cancer Drugs Production Capacity (2016-2026) & (K Units)
Figure 39. Global Ovarian Cancer Drugs Production Capacity by Geographic Region: 2020 VS 2021
Figure 40. Ovarian Cancer Drugs Market Drivers
Figure 41. Ovarian Cancer Drugs Market Restraints
Figure 42. Ovarian Cancer Drugs Market Trends
Figure 43. Global Ovarian Cancer Drugs Sales Market Share by Manufacturer in 2020
Figure 44. Global Ovarian Cancer Drugs Revenue Market Share by Manufacturer in 2020
Figure 45. Ovarian Cancer Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
Figure 46. Top 3 Ovarian Cancer Drugs Manufacturer (Revenue) Market Share in 2020
Figure 47. Top 6 Ovarian Cancer Drugs Manufacturer (Revenue) Market Share in 2020
Figure 48. Global Ovarian Cancer Drugs Sales Market Share by Region (2016-2026)
Figure 49. Global Ovarian Cancer Drugs Revenue Market Share by Region (2016-2026)
Figure 50. North America Ovarian Cancer Drugs Revenue (2016-2026) & (USD Million)
Figure 51. Europe Ovarian Cancer Drugs Revenue (2016-2026) & (USD Million)
Figure 52. Asia-Pacific Ovarian Cancer Drugs Revenue (2016-2026) & (USD Million)
Figure 53. South America Ovarian Cancer Drugs Revenue (2016-2026) & (USD Million)
Figure 54. Middle East & Africa Ovarian Cancer Drugs Revenue (2016-2026) & (USD Million)
Figure 55. Global Ovarian Cancer Drugs Sales Market Share by Type (2016-2026)
Figure 56. Global Ovarian Cancer Drugs Revenue Market Share by Type (2016-2026)
Figure 57. Global Ovarian Cancer Drugs Price by Type (2016-2026) & (USD/Unit)
Figure 58. Global Ovarian Cancer Drugs Sales Market Share by Application (2016-2026)
Figure 59. Global Ovarian Cancer Drugs Revenue Market Share by Application (2016-2026)
Figure 60. Global Ovarian Cancer Drugs Price by Application (2016-2026) & (USD/Unit)
Figure 61. North America Ovarian Cancer Drugs Sales Market Share by Country (2016-2026)
Figure 62. North America Ovarian Cancer Drugs Revenue Market Share by Country (2016-2026)
Figure 63. North America Ovarian Cancer Drugs Sales Market Share by Type (2016-2026)
Figure 64. North America Ovarian Cancer Drugs Sales Market Share by Application (2016-2026)
Figure 65. Europe Ovarian Cancer Drugs Sales Market Share by Country (2016-2026)
Figure 66. Europe Ovarian Cancer Drugs Revenue Market Share by Country (2016-2026)
Figure 67. Europe Ovarian Cancer Drugs Sales Market Share by Type (2016-2026)
Figure 68. Europe Ovarian Cancer Drugs Sales Market Share by Application (2016-2026)
Figure 69. Asia-Pacific Ovarian Cancer Drugs Sales Market Share by Region (2016-2026)
Figure 70. Asia-Pacific Ovarian Cancer Drugs Revenue Market Share by Region (2016-2026)
Figure 71. Asia-Pacific Ovarian Cancer Drugs Sales Market Share by Region (2016-2026)
Figure 72. Asia-Pacific Ovarian Cancer Drugs Sales Market Share by Application (2016-2026)
Figure 73. South America Ovarian Cancer Drugs Sales Market Share by Country (2016-2026)
Figure 74. South America Ovarian Cancer Drugs Revenue Market Share by Country (2016-2026)
Figure 75. South America Ovarian Cancer Drugs Sales Market Share by Type (2016-2026)
Figure 76. South America Ovarian Cancer Drugs Sales Market Share by Application (2016-2026)
Figure 77. Middle East & Africa Ovarian Cancer Drugs Sales Market Share by Country (2016-2026)
Figure 78. Middle East & Africa Ovarian Cancer Drugs Revenue Market Share by Country (2016-2026)
Figure 79. Middle East & Africa Ovarian Cancer Drugs Sales Market Share by Type (2016-2026)
Figure 80. Middle East & Africa Ovarian Cancer Drugs Sales Market Share by Application (2016-2026)
Figure 81. Sales Channel: Direct Channel vs Indirect Channel
Figure 82. Methodology
Figure 83. Research Process and Data Source
卵巣がん薬の世界市場予測 2023年：メーカー別、地域別、種類・用途別 Ovarian cancer is regarded as one of the most common types of cancer among women. It accounts for more deaths than any other cancer of the female reproductive system, while it ranks 5th in overall women deaths due to cancer. This type of cancer is rarely diagnosed at an early stage, making treatment…- 卵巣がんの遺伝子治療の世界市場予測 2023年：メーカー別、地域別、種類・用途別 Ovarian cancer occurs and arises from several types of cells within the ovary, and it has the lowest survival rate of all gynecological cancers. Among many types, epithelial ovarian cancer (EOC) is the most common ovarian cancer, whereas ovarian low malignant potential tumor (OLMPT), germ cell tumor…
- 卵巣がんの世界市場予測 2023年：メーカー別、地域別、種類・用途別 Ovarian cancer is a type of cancer that begins in the ovaries. Ovarian cancer is the most common type of cancer among women. Epithelial tumor, stromal tumor and germ cell tumors are the type of ovarian cancer. Scope of the Report: This report studies the Ovarian Cancer market status and outlook of G…
- 頭頸部がん：頭頸部がん薬物療法の世界市場2018-2025 Head and neck cancer is a group of cancers that starts in the mouth, nose, throat, larynx, sinuses, or salivary glands.Current trends indicate that rising geriatric population worldwide, growing cases of target diseases, and availability of improved healthcare services due to government and private …
- 世界の結腸直腸がん治療薬市場 2021：企業別、地域別、種類・用途別 The Colorectal Cancer Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulat…